Firm
Alexander Bjørnå, aera’s first hire in Norway, explains why it’s the right time to disrupt the country’s ‘traditional’ IP market
Natasha Ahmed said she was drawn to the firm’s commitment to artificial intelligence and tech transactions
As it celebrates its 50th anniversary this year, the firm discusses private equity interest in IP, why the UPC is a key priority, and being a ‘strategic adviser’ to clients
Thomas Rukin discusses IP due diligence, his joy at seeing colleagues succeed, and taking inspiration from Marcus Aurelius
Sponsored
Sponsored
-
Sponsored by Tilleke & GibbinsSon Thai Hoang and Linh Thi Mai Nguyen of Tilleke & Gibbins highlight the strict stance taken by the Intellectual Property Office of Vietnam on assignments conflicting with trade names and join the calls for clearer guidance -
Sponsored by Tilleke & GibbinsThe Central Intellectual Property and International Trade Court has confirmed that a design’s overall appearance should be considered when determining its eligibility for patent protection, report Nuttaphol Arammuang and Tanapong Pongburanakit of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law reports on a decision that should provide improved guidance in determining whether patents or approved drugs are eligible for a patent term extension in South Korea
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Shipra Alisha Philip of RNA, Technology and IP Attorneys analyse how a US ruling could affect digital libraries, e-book licensing, and public access to knowledge in India
-
Sponsored by Bird & BirdEmilia Zalewska and Andrzej Stelmachowski of Bird & Bird provide insights into two matters considered by the Unified Patent Court and a Polish court concerning the imminent infringement of patent rights in the pharmaceutical industry
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies
